AbbVie Inc.’s marketing of its testosterone replacement therapy AndroGel was part of an “insidious” plan to up its profits, argued attorneys for a man suing AbbVie over claims that the drug company didn’t study AndroGel’s cardiovascular risks. Jeffrey Konrad claims he used AndroGel for a few months before suffering a heart attack in 2010. He alleges that AbbVie was aware at that time that testosterone treatments were linked to cardiovascular risks, including heart attacks, strokes, and blood clots – all of which could be fatal. But AbbVie failed to adequately warn Konrad or his doctor of the risks so that ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.